Scientific Research Publishing

Journal of Cancer Therapy, 2021, 12, 577-578
https://www.scirp.org/journal/jct
ISSN Online: 2151-1942
ISSN Print: 2151-1934

Erratum to "Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer" [Journal of Cancer Therapy, 6, 1083-1092]

Ruixia Guo*, Xinyan Wang, Ruifang Zhang, Huirong Shi, Yuhuan Qiao, Wenjing Yun, Xin Ge, Yan Lin, Jia Lei

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Email: *wxinyan001@126.com

How to cite this paper: Guo, R.X., Wang, X.Y., Zhang, R.F., Shi, H.R., Qiao, Y.H., Yun, W.J., Ge, X., Lin, Y. and Lei, J. (2021) Erratum to "Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer" [Journal of Cancer Therapy, 6, 1083-1092]. *Journal of Cancer Therapy*, **12**, 577-578.
https://doi.org/10.4236/jct.2021.1210048

The original online version of this article (Guo, R., Wang, X., Zhang, R., Shi, H., Qiao, Y., Yun, W., Ge, X., Lin, Y. and Lei, J. (2015) Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer. Journal of Cancer Therapy, 6, 1083-1092. https://doi.org/10.4236/jct.2015.612118) was published in November 2015. The authors wish to correct the following error.

The original version of **Figure 3** is inappropriate. We replace **Figure 3** with the following figure:

Received: October 1, 2021
Accepted: October 25, 2021
Published: October 28, 2021



Figure 3. H/E staining (×40) of xenograft tumors. Representative H/E-stained sections of Ishikawa (A)-(D) and HEC-1A cell (E)-(H) xenografts in different groups. Compared with the controls, the number of tumor cells decreased and the number of nuclei decreased by varying degrees in groups treated with PD98059, LY294002 or a combination of both.